Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PI-88 with Docetaxel in Advanced NSCLC
NCT00103389Phase 2Completed
- Sponsor
- Cellxpert Biotechnology Corp.
- Start
- Feb 2004
- Primary completion
- May 2007
- Modality
- Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of Muparfostat in non-small cell lung cancer (NSCLC), sponsored by Cellxpert Biotechnology Corp.. Started Feb 2004; status: completed.
02
Drugs
Muparfostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00103389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00103389.